DOCUMENTO DE CONSENSO SOBRE EL USO DE ANTINEOPLÁSTICOS ORALES.
CONSENSUS STATEMENTS AND POSITION PAPERS
- 10 COMMON CHALLENGES FACED BY HOSPITAL PHARMACY AND ONCOLOGY UNITS (2021)
- CLINICAL INTERVIEW
- 2021-2025 STRATEGIC PLAN
- RED C (C NETWORK) (2021)
- THE CMO MODEL FOR CANCER AND HEMATOLOGICAL PATIENTS (2020)
- SEFH’S POSITION PAPER ON THE NEW ANTINEOPLASTIC MEDICATIONS (2019)
- CAR-T CELL THERAPY MANAGEMENT PROCEDURE (2019)
- PHARMACEUTICAL VALIDATION OF MEDICAL PRESCRIPTIONS FOR HEMATO-ONCOLOGICAL PATIENTS (2018)
- SEFH’S POSITION PAPER ON BIOSIMILAR DRUGS (2017)
- STRATEGIC PLAN ON THE PHARMACEUTICAL CARE OF HEMATO-ONCOLOGICAL PATIENTS (2016)
- POSITION PAPER ON THE ACCESS TO NEW ANTINEOPLASTIC MEDICATION (2015)
- CONSENSUS STATEMENTS